Annual Meeting 2011

Annual Meeting 2011

Tues 8th – Wed 9th November 2011

Maritime Museum, Liverpool, UK

PROGRAMME (Speaker abstracts can be read here)

Session 1: Nanotoxicology
Using in vitro models to assess the toxicity of nanomaterials.
Professor Vicki Stone, Herriot-Watt University

Investigating the nanoparticle-cell interaction in vitro: an advantageous ‘alternative’ approach?.
Dr Martin Clift, Inselspital University Hospital, University of Bern

In vitro testing of immunomodulatory and cytotoxic effects of nanomaterials.
Dr Gertie Oostingh, University of Salzburg

Session 2: Organelle toxicity: Mitochondria and ER toxicity
Introduction and mechanistic insights into mitochondrial-based cellular toxicity.
Dr James Dykens, EyeCyte Therapeutics

Mitochondrial protein profiling and bioenergetics: an in vitro perspective.
Dr Kelvin Cain, MRC Toxicology Unit, University of Leicester

Special workshop: Detection of mitochondrial toxicants in mouse ESC derived cardiomyocytes.
Dr Silke Schwengberg, Axiogenesis/ Lonza

ER Stress: Mechanisms and Toxicological Consequences.
Dr George Kass, EFSA

Defining the role of the mitochondrion and oxidative stress in the chemical and molecular mechanisms of drug-induced cell death.
Dr Amy Mercer, University of Liverpool

Special workshop.
Seahorse Bioscience

Session 3: Regulatory aspects, emerging technologies and validation
Non-animal methods in risk assessment of consumer products.
Penny Jones, Unilever SEAC

In Vitro Tests, Validation and International Adoption.
Ian Indans, Health and Safety Executive

The European Union strategy in addressing nanotoxicology challenges for research and regulatory purposes.
Dr Georgios Katalagarianakis, European Commission, DG Research

Session 4 Free Communications

In vitro cell viability and uptake assessment of pristine and functionalized metal oxide nanoparticles.
Ezequiel Mas del Molino, LEITAT Technological Center

A proliferation assay using human valvular interstitial cells for evaluation of potential cardiac side-effect liability of drug candidates.
Dr Mark O’Connor, Asterand UK Ltd

Development and validation of mechanisms-based in vitro transformation assays for carcinogen screening.
Dr Hemad Yasaei, Brunel University

Special workshop: CRACK IT – Challenge led innovation in the biosciences
Dr Anthony Holmes, NC3Rs

Special workshop: Assay your cells in 3D.
Dr Antony Rutt, Insphero AG, Zurich

Session 5 Emerging liver cell technologies: stem cells and 3D culture models

Developing the potential of human pluripotent stem cell derived hepatocytes for toxicology.
Professor Lorraine Young, University of Nottingham

Toxicology applications of embryonic & induced pluripotent stem cell-derived hepatocytes.
Dr Christopher Goldring, University of Liverpool

Biological phenotype of 3D liver models: our current understanding, benefits and limitations.
Dr Cliff Rowe, University of Manchester

Toxicology applications of 3D liver models.
Dr Simon Messner, InSphero AG, Zurich

Leave a Reply

Your email address will not be published.